Skip to main content
SpringerLink
Log in

Management of Patients with Metastatic Carcinoma of the Bladder

  • Chapter
Carcinoma of the Bladder

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 163 Accesses

Abstract

Survival in untreated patients with metastatic carcinoma of the bladder is poor, the median survival being 3 months (Babaian et al. 1980). The current therapy of choice is combination chemotherapy, which is given with palliative intent, although some long-term survivors have been reported after achieving a complete response on chemotherapy. No clinical trials have been performed on treatment with chemotherapy versus best supportive care. Nevertheless, results from studies on prognostic factors and from phase III clinical trials support a beneficial effect of chemotherapy on survival in metastatic urothelial cancer. In most studies, data on urothelial cancer from different localizations have been clustered, as no differences in prognosis seem to exist between them.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Babaian RJ, Johnson DE, Llamas L, Ayala AG (1980) Metastases from transitional cell carcinoma of urinary bladder. Urology 16: 142–144

    Article  PubMed  CAS  Google Scholar 

  • Bellmunt J, Albanell J, Gallego OS, et al. (1992) Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 70: 1974–1979

    Article  PubMed  CAS  Google Scholar 

  • Bellmunt J, Ribas A, Bermejo B, et al. (1996) M-VAC versus M-CAVI (methotrexate, carboplatin, vinblastine) in advanced surgically incurable bladder cancer. Proc Am Soc Clin Oncol 15: 265

    Google Scholar 

  • Boutan-Laroze A, Mahjoubi M, Droz JP, et al. (1991) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers Experience. Eur J Cancer 27: 1690–1694

    Article  PubMed  CAS  Google Scholar 

  • Carmichael J, Cornbleet MA, MacDougall RH, Allan SG, Duncan W, Chisholm GD, Smyth JF (1985) Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract. Br J Urol 57: 299–302

    Article  PubMed  CAS  Google Scholar 

  • Connor JP, Olsson CA, Benson MC, Rapoport F, Sawczuk IS (1989) Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of the urinary bladder: cause for concern. Urology 34: 353–356

    Article  PubMed  CAS  Google Scholar 

  • De Lena M, Gridelli C, Lorusso V, et al. (1996) Gemcitabine activity (objective response and symptom improvement) in resistant stage IV bladder cancer. Proc Am Soc Clin Oncol 15: 246

    Google Scholar 

  • Dimopoulos MA, Kyriakakis Z, Kostakopoulos A (1996) Cisplatin, ifosfamide, methotrexate and vinblastine (CIMV) combination chemotherapy for metastatic urothelial cancer. Proc Am Soc Clin Oncol 15: 255

    Google Scholar 

  • Dreicer R, Gustin D, See WA, Williams RD (1996) Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. Proc Am Soc Clin Oncol 15: 242

    Google Scholar 

  • Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ (1994) Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12: 2271–2276

    PubMed  CAS  Google Scholar 

  • FossÃ¥. SD, Sager EM, Hosbach G, Waehre H, Ous S (1990) Cisplatin and medium dose methotrexate in advanced transitional cell carcinoma of the urinary tract. Scand J Urol Nephrol 24: 199–204

    Article  PubMed  Google Scholar 

  • Gabrilove JL, Jakubowski A, Scher H, et al. (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414–1422

    Article  PubMed  CAS  Google Scholar 

  • Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A (1991) Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 67: 1525–1531

    Article  PubMed  CAS  Google Scholar 

  • Harker WG, Meyers FJ, Freiha FS, et al. (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J Clin Oncol 3: 1463–1470

    PubMed  CAS  Google Scholar 

  • Hillcoat BL, Raghavan D, Matthews J, et al. (1989) A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7: 706–709

    PubMed  CAS  Google Scholar 

  • Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T (1990) Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144: 662–665

    PubMed  CAS  Google Scholar 

  • Igawa M, Ohkuchi T, Ueda M, Usui T, Kawanishi M (1991) Analyses of factors affecting the outcome of combination chemotherapy in patients with advanced bladder cancer. Eur Urol 20: 12–15

    PubMed  CAS  Google Scholar 

  • Igawa M, Ohkuchi T, Ueda M, Usui T (1992) Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, Adriamycin and cisplatin. Cancer Chemother Pharmacol 30 (Suppl): S77–S80

    Article  PubMed  Google Scholar 

  • Jeffery GM, Mead GM (1992) CMV chemotherapy for advanced transitional cell carcinoma. Br J Cancer 66: 542–546

    Article  PubMed  CAS  Google Scholar 

  • Khandekar JD, Elson PJ, DeWys WD, et al. (1985) Comparative activity and toxicity of cisdiamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide and DDP in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3: 539–545

    PubMed  CAS  Google Scholar 

  • Kotake T, Akaza H, Isaka S, et al. (1992) Evaluation of systemic chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin for advanced bladder cancer 30 (Suppl): S85–S89

    Google Scholar 

  • Lee M-H, Chen MT, Chen KK, et al. (1992) Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract-a preliminary report. Cancer Chemother Pharmacol 30 (Suppl): S81–S84

    Article  PubMed  Google Scholar 

  • Loehrer PJ, Einhorn LH, Elson PJ, et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 10: 1066–1073

    PubMed  Google Scholar 

  • Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH (1994) Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 12: 483–488

    PubMed  Google Scholar 

  • Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, Pilat S (1989) Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol 141: 33–37

    PubMed  CAS  Google Scholar 

  • Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990a) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050–1055

    PubMed  CAS  Google Scholar 

  • Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU (1990b) Escalated therapy for refractory urothelial tumors: methotrexate-vinblastinedoxorubicin-cisplatin plus unglycolylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 82: 667–672

    Article  PubMed  CAS  Google Scholar 

  • Logothetis C, Finn L, Amato R, Hossan E, Sella A (1992) Escalated MVAC +/- rhGM-CSF (Schering-Plough) in metastatic transitional cell carcinoma: preliminary results of a randomized trial. Proc Am Soc Clin Oncol 11: 202

    Google Scholar 

  • Logothetis CJ, Hossan E, Recondo G, et al. (1994) 5Fluorouracil and interferon-α in chemotherapy refractory bladder carcinoma: an effective regimen. Anticancer Res 14: 1265–1270

    PubMed  CAS  Google Scholar 

  • Maru A, Akaza H, Isaka S, et al. (1987) Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and 5fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder. Cancer Chemother Pharmacol 20 (Suppl): S44–S48

    Article  PubMed  Google Scholar 

  • McCaffrey J, Hilton S, Mazumdar M, et al. (1996) A phase II trial of ifosfamide, paclitaxel and cisplatin (ITP) in patients with advanced urothelial tract tumors. Proc Am Soc Clin Oncol 15:251

    Google Scholar 

  • Mead GM, Crook AM, Russell JM, et al. (1996) An MRC randomised trial comparing MV (methotrexate and vinblastine) with CMV (cisplatin + MV) for metastatic transitional cell cancer. Proc Am Soc Clin Oncol 15: 241

    Google Scholar 

  • Moore MJ, Iscoe N, Tannock IA (1993) A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 150: 1131–1134

    PubMed  CAS  Google Scholar 

  • Moore MJ, Tannock I, Ernst S, Huan S, Murray N (1996) Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 15: 250

    Google Scholar 

  • Mulder JH, FossÃ¥ SD, De Pauw M, Van Oosterom AT (1982) Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study. Eur J Cancer 18: 111–112

    Article  CAS  Google Scholar 

  • Murphy BA, Johnson DR, Smith J, Koch M, DeVore R, Blanke C, Johnson DR (1996) Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Am Soc Clin Oncol 15: 245

    Google Scholar 

  • Ogawa T, Gotoh A, Takenaka A, et al. (1992) Clinical and pathological evaluations of methotrexate, vinblastine, Adriamycin and cisplatin chemotherapy for advanced urothelial cancers. Cancer Chemother Pharmacol 30 (Suppl): S66–S71

    Article  PubMed  Google Scholar 

  • Oliver RTD, Kwok HK, Highman WJ, Waxman J (1986) Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer. Br J Urol 58: 31–35

    Article  PubMed  CAS  Google Scholar 

  • Pizzocaro G, Milani A, Piva L, Faustini M, Spino E (1991) Methotrexate, vinblastine, Adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study. Eur Urol 20: 89–92

    PubMed  CAS  Google Scholar 

  • Pollera CF, Ceribelli A, Crecco M, Calabresi F (1994) Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5: 182–184

    PubMed  CAS  Google Scholar 

  • Roth BJ, Dreicer R, Einhorn LH, et al. (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264–2270

    PubMed  CAS  Google Scholar 

  • Saxman SB, Loehrer PJ, Propert K, et al. (1996) Long-term follow up of phase III intergroup study of M-VAC vs cisplatin in metastatic urothelial carcinoma. Proc Am Soc Clin Oncol 15: 248

    Google Scholar 

  • Scher HI, Geller NL, Curley T, Tao Y (1993) Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 11: 400–407

    PubMed  CAS  Google Scholar 

  • Schwartz S, Yagoda A, Natale RB, Watson RC, Whitmore WF, Lesser M (1983) Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors. J Urol 130: 681–684

    PubMed  CAS  Google Scholar 

  • Seidman AD, Scher HI, Heinemann MH, et al. (1991) Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68: 2561–2565

    Article  PubMed  CAS  Google Scholar 

  • Seidman AD, Scher HI, Gabrilove JL, et al. (1993) Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11: 408–414

    PubMed  CAS  Google Scholar 

  • Seligman PA, Crawford ED (1991) Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst 83: 1582–1584

    Article  PubMed  CAS  Google Scholar 

  • Sengelav L, Kamby C, Schou G, Von der Maase H (1994) Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer 74: 123–133

    Article  Google Scholar 

  • Soloway MS, Einstein A, Corder MP, Bonney W, Prout GR, Coombs J (1983) A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study. Cancer 52: 767–772

    Article  PubMed  CAS  Google Scholar 

  • Splinter TAW, Scher HI, Denis L, et al. (1992) The prognostic value of the pathological response to combination chemotherapy prior to cystectomy in patients with invasive bladder cancer. J Urol 147: 606–608

    PubMed  CAS  Google Scholar 

  • Stadler W, Kuzel T, Raghavan D, Levine E, Vogelzang N, Dorr FA (1995) A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 14: 241

    Google Scholar 

  • Sternberg CN, Yagoda A, Scher HI (1988) M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461–469

    PubMed  CAS  Google Scholar 

  • Sternberg CN, Yagoda A, Scher HI, et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448–2458

    Article  PubMed  CAS  Google Scholar 

  • Sternberg CN, De Mulder PHM, Van Oosterom AT, Fossa SD, Giannarelli D, Soedirman JR (1993) Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann Oncol 4: 403–407

    PubMed  CAS  Google Scholar 

  • Stoter G, Splinter TAW, Child JA, et al. (1987) Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137: 663–667

    PubMed  CAS  Google Scholar 

  • Tannock I, Gospodarowicz M, Connolly J, Jewett M (1989) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 142: 289–292

    PubMed  CAS  Google Scholar 

  • Troner MB, Hemstreet GP (1981) Cyclophosphamide, doxorubicin, and cisplatin (CAP) in the treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep 65: 29–32

    PubMed  CAS  Google Scholar 

  • Troner M, Birch R, Omura GA, et al. (1987) Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group Trial. J Urol 137: 660–662

    PubMed  CAS  Google Scholar 

  • Ueki O, Hisazumi H, Uchibayashi T, et al. (1992) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer. Cancer Chemother Pharmacol 30 (Suppl): S72–S76

    Article  PubMed  Google Scholar 

  • Vaughn DJ, Malkowicz SB, Zoltick B, et al. (1996) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: a well-tolerated outpatient regimen. Proc Am Soc Clin Oncol 15: 240

    Google Scholar 

  • Witte R, Loehrer P, Dreicer R, Williams S, Elson P (1993) Ifosfamide in advanced urothelial carcinoma: an ECOG trial. Proc Am Soc Clin Oncol 12: 230

    Google Scholar 

  • Yagoda A (1987) Chemotherapy of urothelial tract tumors. Cancer 60: 574–585

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rotterdam Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands

    C. C. D. Van Der Rijt MD

  2. University Hospital Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands

    T. A. W. Splinter MD

Authors
  1. C. C. D. Van Der Rijt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. A. W. Splinter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of Southern California, USC/Norris Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA

    Zbigniew Petrovich MD, FACR (Professor and Chairman) (Professor and Chairman)

  2. Department of Urology, UZ Gasthuisberg, University of Leuven, Herestraat 49, B-3000, Leuven, Belgium

    Luc Baert MD, PhD (Professor and Chairman) (Professor and Chairman)

  3. Department of Radiation Oncology and Nuclear Medicine, Allegheny University Hospitals, Center City, Mail Stop 200, Broad & Vine Sts., Philadelphia, PA, 19102-1192, USA

    Luther W. Brady MD (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Van Der Rijt, C.C.D., Splinter, T.A.W. (1998). Management of Patients with Metastatic Carcinoma of the Bladder. In: Petrovich, Z., Baert, L., Brady, L.W. (eds) Carcinoma of the Bladder. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60258-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60258-0_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64323-1

  • Online ISBN: 978-3-642-60258-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation